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A case report of a child with sepsis induced
multiorgan failure and massive complement
consumption treated with a short course of
Eculizumab
A case of crosstalk between coagulation and complement?
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∗
,
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Abstract
Rationale: This article describes a child with a life-threatening multiorgan failure with disseminated intravascular coagulation (DIC)
and massive complement consumption. To our knowledge this therapeutic approach was for the ﬁrst time effectively applied in a
pediatric patient.
Patient concerns: A 14-month-old boy was presented with a severe, rapidly progressing, life-threatening disease because of
sudden onset of fever, hemathemesis, hematuria, and bloody diarrhoea alongside fast spreading hematomas and general corporeal
edema.
Diagnosis: The most plausible diagnosis in our patient is Clostridium difﬁcile sepsis-induced thrombotic microangiopathy
alongside with DIC and consumption coagulopathy. The diagnosis was conﬁrmed by positive C difﬁcile bacteria strain in
coproculture, clinical, and laboratory tests afﬁrming DIC and global complement activation and consumption.
Interventions: The patient was treated with antibiotics (Metronidazole, Vancomycin), plasmapheresis, dialysis, methylpredniso-
lone, mycophenolate mofetil, and Eculizumab.
Outcomes: The child is in fair overall condition in a 2 year follow-up with no complications save chronic renal failure.
Lessons: In rare cases of sepsis with massive complement consumption, a case-sensitive Eculizumab therapy may be at least
considered after the resolution of life-threatening multiorgan failure. The application of this drug can be performed only after sepsis
induced disease is put under control. A fast withdrawal of Eculizumab after control of massive complement consumption is
recommended to prevent triggering of second sepsis reactivation.
Abbreviations: AP = alternative pathway, aPTT = activated partial thromboplastin time, CD46 =membrane cofactor protein 46,
CFB = complement factor B, CFH = complement factor H, CFHR5 = complement factor H-related protein 5, CFI = complement
factor I, DGKE = diacylglycerol kinase-epsilon, HUS = hemolytic-uremic syndrome, MOF = multiorgan failure, PNH = paroxysmal
nocturnal hemoglobinuria, PT = prothrombin time, RBC = red blood cell, THBD = thrombomodulin, TMA = thrombotic
microangiopathy, TTP = thrombotic thrombcytopenic purpura.
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1. Introduction
Clostridium difﬁcile (C difﬁcile) colitis is constantly an increasing
cause of severe infection disease in children.[1,2] A child with life-
threatening multiorgan failure (MOF) caused by C difﬁcile is still
considered as a challenge for the most plausible treatments.[1,3]
Eculizumab, a humanized anti-C5 monoclonal antibody that
inhibits terminal pathway activation by blocking the generation
of C5b-9 (membrane attack complex) is currently considered as
an effective and safe choice for the treatment of patients with
uncontrolled complement consumption. Herein, we present a
child with MOF and massive complement consumption caused
by acute C difﬁcile colitis who among other acknowledged
treatment also received a short course of Eculizumab.
2. Case presentation
A 14-month-old boy with severe, rapidly progressing, life-
threatening disease was admitted in intensive care unit because of
sudden onset of fever, hemathemesis, hematuria, and bloody
diarrhoea alongside fast spreading hematomas and general
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corporeal edema. A day before onset of the disease the child
consumed a small portion of plant soil. Sedation was performed
with the goal of life-saving interventions tolerance, blood
pressure was maintained via medications and as oliguria/anuria
soon progressed a continuous veno-venous hemodialysis was set
forth. Anuria was maintained throughout the disease. Previously
he was a healthy child with no relevant medical history of similar
disease or in family history. No prodromal symptoms were
noticed.
Relevant clinical, laboratory, diagnostic, and medication
follow-up is shown in Figure 1. The initial presentation of
MOF begun with sepsis including gastrointestinal, renal, cardiac,
Figure 1. Clinical, laboratory, and treatment time-line of our case.
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and liver impairment. Life-threatening anemia and thrombocy-
topenia required frequent packed RBC and platelet transfusions,
avoided as much as possible. Massive bloody diarrhoea was
lasting during the ﬁrst 10 days following by hose outﬂow.
Bleeding edematous gut mucosa was visualized by colonoscopy
without signs of intestinal perforation. The child received initially
multiple fresh frozen plasma infusions and a short course of
plasma exchange with plasma replacement during 4 consecutive
days, until stabile vital functions were achieved. Kidney
ultrasound showed hyperechogenic kidneys without cortico-
medullar differentiation. As positive C difﬁcile bacteria was
isolated in 2 separate coprocultures by 2 independent laborato-
ries, Metronidazole and Vancomycin were administered. Unfor-
tunately, due to technical difﬁculties we did not achieve positiveC
difﬁcile toxin identiﬁcation. Shiga toxin was proved negative as
well as E. coli, Shigella sp., Streptococcus pneumoniae,
Campylobacter sp., and other bacteria causing HUS. Extensive
search for poisonous substances were proved negative alongside
with PNH, methylmalonic aciduria and homocystinuria. No
fragmentocytes were found in periferal blood. Direct Coombs test
was negative.
Coagulation tests revealed normal prothrombin time (PT),
elevated activated partial thromboplastin time (aPTT), and
increased D-dimers. Fibrinogen was found within normal range.
LDH and free hemoglobin were elevated from the beginning of
the disease. Antithrombin III values were low and slowly
improved during time. All values were tested according to ISTH
diagnostic scoring system for DIC guidelines and found negative
<5.[4–6] Haptoglobin values were low from the beginning of the
disease. C3, factor H levels, and alternative pathway (AP) activity
were decreased, without elevation of complement activation
markers sC5b9 or C3a. This is probably due to a protein-loss
related activity rather than activation and consumption. C1q was
severely decreased and with negative anti-C1q, supporting the
presence of global complement activation and consumption.
Decreased but not deﬁcient ADAMTS13metalloprotease activity
(46%) excluded thrombotic thrombcytopenic purpura (TTP).
Liver enzymes (AST, ALT, GGT) were elevated from the
beginning of the disease. Vitamin K was supplemented.
Immunoglobulins levels (IgG, IgA, and IgM) were found to be
lower for the age and in need of occasional substitution even after
active disease ceased. Abdominal and brain CT scans were
proven negative for gut perforation or brain damage.
From clinical judgment and laboratory ﬁndings (normal plasma
ﬁbrinogen, elevated D-dimers and free hemoglobin, low hapto-
globin and decreased platelets), as well as alternative pathway
activation indicating the presence of severe, global complement
activation and consumption, we suspected of uncontrollable
complement regulator loss and activation process underway the
infective C difﬁcile disease trigger. Therefore, a secondary
thrombotic microangiopathy (TMA) triggered by the infection
and by the coagulopathy was assumed. Negative complement
activation marker sC5b9 may be explained by plasma sample
collection which was taken before ongoing TMA activation.
After administration of Eculizumab in dosage on 10th day of
the disease (600mg) the patient’s physical condition soon
improved with ceasing of bloody diarrhoea. Second onset of
bloody diarrhoea after 5 days also ceased with the second dose of
Eculizumab (300mg). Small amount of bloody diarrhoea was
again noticed after 1 month of last Eculizumab administration
but treated via symptomatic medications. After administration of
Eculizumab, a rapid improvement and normalization of platelets
and other hematologic data were noticed alongside with further
signiﬁcant clinical improvement. Haptoglobin level was normal-
ized 6 weeks after the administration of Eculizumab. As patient’s
clinical state and laboratory values were normalized and with
negative support from kidney biopsy, we decided to cease further
use of Eculizumab.
As elevation of liver enzymes continued throughout the
course of the disease, a liver biopsy was performed showing no
tissue pathology. Kidney biopsy was performed 1 week after
the start of Eculizumab treatment and showed interstitial
nephritis. Therefore, a pulse methylprednisolone therapy (5
days of duration) was administered followed by oral
methylprednisolone therapy during following month. As
kidney function was not improved, a second kidney biopsy
was performed with the same histological features. A second
pulse of methylprednisolone was thus performed 2 months
after the ﬁrst one, followed by oral mycofenolate mofetil with
no recovery of kidney function afterward. Soon after
methylprednisolone/mycofenolate use all liver enzymes fall to
normal values after 6 months of its continuous elevation. Other
supportive therapy (i.v. immunoglobulins) were also periodi-
cally administered. During the genetic workup, the whole
coding regions of the genes encoding complement factor H
(CFH), complement factor H-related protein 5 (CFHR5), factor
I (CFI), membrane cofactor protein (CD46), thrombomodulin
(THBD), factor B (CFB), C3 (C3), and diacylglycerol kinase-
epsilon (DGKE) were analyzed by direct DNA sequencing
following PCR ampliﬁcation. The patient was found to be
heterozygous for a substitution in exon 2 of the CFHR5 gene
(c.136C>T) causing a proline to serine change at codon 46 of
the complement factor H-related protein 5 (p. P46S),
interpreted as variant with unknown functional signiﬁcance.
Furthermore, the CFH H3 haplotype was identiﬁed in the
patient, reported as a risk factor of aHUS.
3. Discussion
Since verotoxin test was negative, and the disease showed
unusually severe course with MOF, typical HUS could be
excluded safely despite obvious triggering of the disease by C
difﬁcile.[7–10] It is possible that the development of secondary
HUS/TTPwas related to severe protein loss, but predisposition by
the presence of CFH H3 aHUS risk haplotype and/or by the p.
P46S CFHR5 mutation should also be considered. Pathogenic
factors identiﬁed for this case may represent rather a continuum:
based on the current pathogenesis model, weak predispositing
factors with strong trigger may jointly lead to the development of
thrombotic microangiopathy. We consider protein loss (loss of
plasma factors and regulators in the GI tract) as the major
obstacle in pathogenesis, which may also explain the lack of
activation product (sC5b9) elevation. Elevated LDH at the
beginning of the disease and free hemoglobin lasting 5 weeks
alongside with elevated D-dimers, low platelets, decreased
ADAMTS13 activity, consistent and long lasting low level of
haptoglobin supports the presence of secondary thrombotic
microangiopathy, manifested asMOF andHUS. Genetic analysis
does not fully support aHUS either. The boy’s mutation was not
described previously in patients with aHUS but was observed in 3
patients with MPGN II/DDD (PMID: 16299065) and also in
healthy subjects with a relatively low frequency (0.8–1.8%).
Based on these data this mutation may or may not have a
pathogenic role in the development of aHUS, and was considered
as variant with unknown functional signiﬁcance. Importantly,
the possibility of thrombotic microangiopathy triggered by
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disseminated intravascular coagulation (DIC)—speciﬁc patholo-
gy seems plausible explanation.[11]
Therefore, one of the most presumable solutions for the
diagnosis in our patient is DIC or consumption coagulopathy
which can arise in sepsis-induced thrombotic microangiopathy
(TMA), especially in severe cases with reduced ADAMTS13
activity.[12–17] The presence of DIC is supported by aPTT
moderate elevation (normalized after 8 days) and reduced
antitrombin III (probably due to protein loss) which lasts 12 days
to full recovery alongside low platelets count.[4,6] A 7 weeks of
elevated plasma D-dimers as well as decreased ADAMTS13
activity are nevertheless consistent with DIC but also with
concomittant TMA.[4] Both, ADAMTS13 and aPTT have
prognostic signiﬁcance for DIC evolution indicating increased
possibility of renal failure.[4,18,19] Normal level of ﬁbrinogen as
well as ISTH score repeatedly negative results are not compatible
with DIC (low plasma ﬁbrinogen is often associated with severe
forms of DIC.[4–6] However, normal level of ﬁbrinogen observed
in severe septic DIC may be due to its substantial overproduction
which compensates the rate of actual consumption.[6] We should
expect prolonged PT (usually >50%) associated with liver
disease, vitamin K deﬁciency and loss of the coagulation proteins
due to massive bleeding.[4] The possible explanation may be
the presence of circulating activated clotting factors, such as
thrombin and Xa.[6]
After successful treatment of sepsis, symptoms of DIC soon
decreased. Eculizumab treatment in sepsis-induced DIC with
decreased ADAMTS13 activity was already successfully admin-
istered in adult patients.[12,13] The same treatment applies for the
secondary TMA.[20] Judging from clinical feature and Eculizu-
mab response, a secondary TMA seems to be probable. It is also
supported by long lasting low level of haptoglobin and platelets
from the beginning of the disease as well as by minor but steady
hemolysis. Fast normalization of LDH is probably partly
explained by plasma exchange. Low C3 supports potential
concurrent TMA as well. Decreased C3, HF, and AP activity may
support complement loss or activation and ongoing TMA;
however, these parameters may also be related to infection
related consumption. Since, due to a technical difﬁculties kidney
biopsy was performed only 1 week after the start of Eculizumab
treatment, it is not possible to draw ﬁrm conclusion about the
presence or absence of TMA before treatment.
A potential crosstalk between complement and coagulation
systems may be involved in our patient as complement is
activated in most patients with DIC and active coagulation
cascade.[11,12,21–23] Some authors suggested that patients with
ampliﬁcation of the complement and coagulation cascades with
clinical progression of the disease may beneﬁt from Eculizumab,
preventing the generation of C5a and membrane attack complex
impairment.[11,23] Rapid clinical and laboratory response (rise of
platelets and C3) after Eculizumab administration best ﬁts such
possibility. Infection with C difﬁcile supports all aforementioned
diagnostic possibilities, (HUS, aHUS, secondary TMA DIC).
Unrecognized immune deﬁciency afore present illness probably
contributed to onset ofC difﬁcile infection-mediated disease since
decreased levels of immunoglobulins (IgG, IgA, IgM) IgG) still
exist after the cease of active disease.
To our best judgement Eculizumab administration in such
clinical cases remains controversial. We are fully aware that if
administered sooner than time-optimal without sufﬁcient infec-
tion control of triggering MOF, Eculizumab might increase the
risk of infection by meningococcus and encapsulated bacteria. By
reducing massive complement activation, Eculizumab may
temporarily help to prevent tissue damage involved in MOF.
We do not recommend Eculizumab administration in all of MOF
patients. Instead, a case-sensitive approach in patients with
massive complement consumption with short course of Eculizu-
mab may be considered as a temporary solution for complement
inhibition. It may look like driving between Scylla and Charybdis
but carefully timing Eculizumab administration will temporary
reduce devastating complement activation and consumption,
minimazing the risk of infection activation. Plausible withdrawal
of the drug by its short course of administration may be the
proper answer.
To our knowledge, this is the ﬁrst report of a child treated with
Eculizumab in such conditions. Carefully monitoring symptoms
and signs of infection with real-time laboratory data and daily
evaluation of patient’s overall condition may lead physicians to
optimal therapy approach. We believe that in similar clinical
circumstances apart from C difﬁcile triggering infection, the
administration of Eculizumab should be at least considered.
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